Medtronic Expands Focus on Interventional Oncology with Its U.S. Launch of OptiSphere(TM) Embolization Spheres
April 17 2018 - 11:00AM
Product Line
Offers Unique, Resorbable Option for Patients with Hypervascular
Tumors
DUBLIN - April 17, 2018 -
Medtronic plc (NYSE: MDT) today announced its U.S. launch of
OptiSphere(TM) embolization spheres, a resorbable embolic platform
designed for embolization of hypervascular tumors. OptiSphere
offers patients an alternative treatment option, a resorbable
embolic, with comparable results to a permanent embolic.1
Hypervascular tumors can present as malignant or
benign and can be found in various anatomical structures.
Physicians may choose to treat these tumors with various therapies
including, but not limited to, embolization, microwave ablation,
radiofrequency ablation, or cryoablation.
"Medtronic continues to seek opportunities to
expand the therapies we offer to patients and the physicians who
treat them. With increased and better quality of care, the cancer
patient population is living longer with the disease and it is
important that we continue to introduce therapies that help
positively impact and improve their quality of life,"said Jeff
Cambra, general manager of the Pain Therapies Interventional
business, which is part of the Restorative Therapies Group at
Medtronic. "We consider this launch to be a win for both sides of
the healthcare pathway, as OptiSphere addresses patient concerns of
having permanent implanted spheres left behind while enabling
physicians to offer an innovative treatment option in their
facilities."
OptiSphere is manufactured for Medtronic by
Vascular Solutions, LLC, a subsidiary of Teleflex Incorporated
(NYSE: TFX). Medtronic continues to partner with the company to
further innovate the technology. OptiSphere received U.S. Food and
Drug Administration (FDA) 510(k) clearance in April 2014.
"Teleflex is very pleased to have Medtronic as a
strategic distribution partner for our novel platform of embolic
spheres," said Jake Isenburg, Ph.D., director of Scientific Affairs
for Teleflex. "The development of unique resorbable implants,
particularly in the field of embolization, has become one of our
core technical competencies at Vascular Solutions and Teleflex. By
combining this technical expertise with Medtronic's focus in
interventional oncology, Teleflex is excited to collaborate on
providing an alternative solution to healthcare professionals who
are seeking a resorbable embolization product."
OptiSphere short-term spheres have shown long-term
results1 and offer an
alternative solution for treating hypervascular tumors. The
resorbable microspheres begin to degrade starting at four weeks
post-procedure with significant degradation noted at nine
weeks.1
The spherical shape of OptiSphere provides smooth
embolic delivery and even, predictable distribution. The product
line offers procedural flexibility with two volume options and five
size ranges which may be combined in a single procedure as needed
to achieve the desired occlusion. Risks of embolization procedures
may include, but are not limited to, non-target embolization and
post-procedure syndrome; please refer to the product instructions
for use for a full listing of the indications, contraindications,
warnings, precautions and potential adverse effects.
About Teleflex
Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people's lives. We apply purpose
driven innovation - a relentless pursuit of identifying unmet
clinical needs - to benefit patients and healthcare providers. Our
portfolio is diverse, with solutions in the fields of vascular and
interventional access, surgical, anesthesia, cardiac care, urology,
emergency medicine and respiratory care. Teleflex employees
worldwide are united in the understanding that what we do every day
makes a difference. For more information, please visit
teleflex.com.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 84,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
1 Data on file
based on animal testing. Pre-clinical studies are not indicative of
human clinical outcomes.
Contacts:
Victor Rocha
Public Relations
+1-901-399-2401
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Sep 2023 to Sep 2024